Why Is Capricor Therapeutics (CAPR) Stock Down -67.51% Today?

Key Takeaways

• Capricor Therapeutics shares plunged approximately 67.5% in Monday trading, falling from a prior close of $19.70 to around $6.40.
• The primary catalyst: FDA staff reviewers released briefing documents ahead of the July 29 advisory committee meeting, raising significant concerns about the effectiveness of deramiocel, the company's lead Duchenne muscular dystrophy (DMD) therapy.
• Historical context weighs heavily: The original Biologics License Application (BLA) for deramiocel received a Complete Response Letter (CRL) in 2025 due to insufficient evidence of effectiveness and an unfavorable benefit-risk assessment.
• Broader pressures compounding the selloff: The stock was already under stress, having shed roughly 33% over the past month amid insider stock sales, Russell index removal, and an ongoing legal dispute with its commercialization partner.
• What traders are watching next: The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting on July 29, followed by the PDUFA target action date of August 22, 2026.

Opening Summary

CAPR, the stock of Capricor Therapeutics, Inc. — a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for rare diseases, most notably Duchenne muscular dystrophy — suffered a catastrophic decline on Monday. Shares cratered roughly 67.51%, tumbling to approximately $6.40 from Friday's closing price of $19.70. The collapse was triggered by the U.S. Food and Drug Administration's release of briefing documents ahead of this week's pivotal advisory committee meeting, in which agency staff reviewers raised pointed concerns about the effectiveness of the company's lead drug candidate, deramiocel.

FDA Briefing Documents Deliver a Devastating Blow

The selloff was ignited in premarket trading after the FDA posted its briefing materials for the July 29 meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC). The committee is convening to review Capricor's resubmitted Biologics License Application for deramiocel, an allogeneic cardiosphere-derived cell therapy proposed for the treatment of cardiomyopathy in male patients with Duchenne muscular dystrophy.

In its briefing documents, the FDA underscored that substantial evidence of effectiveness generally requires at least two adequate and well-controlled clinical investigations, each convincing on its own. The agency highlighted that the original BLA submission — based on results from the Phase 2 HOPE-2 study and its open-label extension — showed no evidence of effectiveness on skeletal or cardiac function as measured by left ventricular ejection fraction and other cardiac parameters. That earlier submission resulted in a Complete Response Letter in 2025, citing a lack of substantial evidence of effectiveness and an unfavorable benefit-risk assessment.

The resubmitted application now rests heavily on data from the Phase 3 HOPE-3 trial, which met its primary endpoint (Performance of Upper Limb v2.0) and a key secondary cardiac endpoint (left ventricular ejection fraction). However, the FDA staff's skeptical tone in the briefing documents suggests the agency remains unconvinced that the totality of evidence meets the high bar for approval, particularly given the single pivotal trial structure and the prior CRL.

A String of Headwinds Already Weighing on the Stock

Monday's collapse did not occur in a vacuum. CAPR shares had already been under considerable pressure in recent weeks. Over the past month alone, the stock had declined roughly 33%, and it was down approximately 44% over the trailing three months. Contributing factors included the company's removal from several Russell indexes during the annual reconstitution, which forced passive funds to shed positions, and insider stock sales by CFO Anthony Bergmann and General Counsel Karen Krasney in late June totaling roughly $1.46 million.

Adding to the uncertainty, Capricor is engaged in ongoing litigation against Nippon Shinyaku and its U.S. subsidiary NS Pharma over the parties' distribution agreement for deramiocel. The legal dispute complicates the commercial picture even if the therapy ultimately secures FDA approval. Meanwhile, the company recently signed a 171,000-square-foot lease for a new headquarters and manufacturing facility in San Diego — a commitment explicitly contingent on FDA approval of deramiocel by December 31, 2026, underscoring how much of the company's future hinges on a single regulatory decision.

Market Context and Trading Activity

Trading volume in CAPR was certain to be massively elevated on Monday, reflecting the binary nature of the FDA development. The stock gapped down sharply at the open, with premarket indications already pointing to a decline exceeding 60%. The move was entirely company-specific and did not reflect broader biotech sector weakness. The SPDR S&P Biotech ETF (XBI) and the iShares Biotechnology ETF (IBB) did not show comparable dislocation. The plunge also meant CAPR traded well below all commonly watched moving averages and at levels not seen since early 2025, before the resubmitted BLA was accepted for review.

What Comes Next for CAPR

The immediate focus for CAPR shareholders is the July 29 advisory committee meeting, where external experts will vote on whether the available data support deramiocel's effectiveness and a favorable risk-benefit profile. While the committee's recommendation is non-binding, the FDA typically follows its advice, and the tone of the staff briefing documents suggests a challenging panel discussion ahead.

Beyond the adcom, the PDUFA target action date of August 22, 2026, represents the definitive binary event. Should the FDA issue a second Complete Response Letter, Capricor's path to commercialization would be substantially delayed, and the economics of its newly signed headquarters lease — which carries nearly $958,000 per month in base rent once abatements expire — would come under intense scrutiny. On the positive side, the company ended Q1 2026 with approximately $278.6 million in cash and marketable securities, providing a runway into the fourth quarter of 2027.

Investors will also be watching for any updates on the NS Pharma litigation, second-quarter earnings expected in early August, and management's commentary on the regulatory path forward following the advisory committee meeting. Given deramiocel's centrality to Capricor's valuation, the stock is likely to remain extraordinarily volatile through the August PDUFA date.

Trending AI Robots

In volatile market environments like the one impacting CAPR today, traders often turn to technology-driven tools to navigate uncertainty. Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that have demonstrated strong performance under current market conditions. With hundreds of bots covering thousands of tickers across diverse strategies, timeframes, and performance metrics, only the top performers make it into this featured lineup. Whether you are looking for short-term momentum plays or longer-term position strategies, the Trending AI Robots page offers a gateway to data-driven trading tools designed to adapt as market conditions evolve.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Notable companies

Industry description

Market Cap

High and low price notable news

Volume